Skip to content

Upexi UPXI Proceeds From The Sale Of Vitamedica Inc

Proceeds From The Sale Of Vitamedica Inc at other companies

Mondelez International logo
Mondelez InternationalMDLZ
$1M-75.0%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$10.37M+313%
PepsiCo logo
PepsiCoPEP
$9.75M-76.5%
Amcor logo
AmcorAMCR
$0-100%
Danaher logo
DanaherDHR
$0-100%
PSK
Paramount Skydance Corporation Class B Common StockPSKY
$11M-82.0%

Other financials

Income statement

See full
Revenue$4.6M+44.2%
Gross profit$4.4M+179%
Operating income-$106.8M-2,877%
Net income-$109.3M-2,754%
EPS (diluted)-$1.67+41.8%

Balance sheet

See full
Cash & equivalents$3.5M+1,412%
Total debt$242.5M+12,119%
Total equity-$51.9M-2,905%
Total assets$200.4M+1,230%

Cash flow

See full
Operating cash flow-$4.8M-513%
CapEx$11.7K-61.7%
Free cash flow-$4.8M-492%

Valuation

See full
Market cap$59.22M-44.5%
Enterprise value$298.19M+121%
P/S2.3×-4.5×

Profitability

See full
Gross margin87%+32.6pp
Operating margin-839.8%-1,002pp
Net margin-874%-1,071pp
FCF margin-83.2%

Returns & leverage

See full
Return on equity-468.5%-935pp
Debt / equity4.4×+3.8×
Current ratio1.7×+1.4×

Where this comes from

Reported directly by Upexi in its filing.

Tagged under the XBRL concept upxi:ProceedsFromTheSaleOfVitamedicaInc.

The official record: Upexi’s 10-K, filed September 24, 2025, on SEC EDGAR. View the filing →

Ask your AI about Upexi's proceeds from the sale of vitamedica inc.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upexi's proceeds from the sale of vitamedica inc?
Upexi (UPXI) reported proceeds from the sale of vitamedica inc of $0 in Q2 2025.
How has Upexi's proceeds from the sale of vitamedica inc changed year-over-year?
Upexi's proceeds from the sale of vitamedica inc decreased by 100.0% year-over-year, from $525K to $0.
What does proceeds from the sale of vitamedica inc mean?
Cash proceeds received from the divestiture of a specific subsidiary or business unit. This reflects the company's strategy regarding portfolio optimization and the realization of value from non-core or matured business segments. It provides insight into the company's capital allocation and divestment execution.